{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:17:23Z","timestamp":1793755043634,"version":"4.6.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.toxicon.2018.01.019","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T17:22:39Z","timestamp":1517678559000},"page":"134-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Evidence on botulinum toxin in selected disorders"],"prefix":"10.1016","volume":"147","author":[{"given":"Elina","family":"Zakin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2018.01.019_bib1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrneurol.2016.86","article-title":"Clinical guidelines: No more mistaken identities for botulinum neurotoxins","volume":"12","author":"Albanese","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.toxicon.2018.01.019_bib2","first-page":"2201","article-title":"Practical guidance for CD management involving treatment of botulinum toxin: a consensus treatment","volume":"262","author":"Albanese","year":"2015","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.toxicon.2018.01.019_bib3","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.parkreldis.2011.06.013","article-title":"Updates on the antinociceptive mechanism hypothesis of botulinum toxin A","volume":"17","author":"Aoki","year":"2011","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.toxicon.2018.01.019_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double - blind, randomized, placebo - controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2018.01.019_bib5","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1177\/0269215513491274","article-title":"The efficacy of Botulinum Toxin A for spasticity and pain in adults: a systematic review and meta-analysis using the Grades of Recommendation Assessment, Development and Evaluation Approach","volume":"12","author":"Baker","year":"2013","journal-title":"Clin. Rehabil."},{"key":"10.1016\/j.toxicon.2018.01.019_bib6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12640-009-9023-3","article-title":"Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs","volume":"15","author":"Bentivoglio","year":"2009","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.toxicon.2018.01.019_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(03)15351-2","article-title":"Sonography-guided injection of botulinum toxin in children with cerebral palsy","volume":"363","author":"Berweck","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.toxicon.2018.01.019_bib8","first-page":"28","article-title":"Sonographic Imaging for guiding botulinum toxin injections in limb muscles","volume":"4","author":"Berweck","year":"2004","journal-title":"Adv Clin Neurosci Rehab"},{"key":"10.1016\/j.toxicon.2018.01.019_bib9","first-page":"654","article-title":"Rationale for study and design of COMPEL: an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumA for headache prophylaxis in adults with chronic migraine","volume":"3","author":"Blumenfeld","year":"2012","journal-title":"F1000Posters"},{"key":"10.1016\/j.toxicon.2018.01.019_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.84.14_supplement.P1.306","article-title":"Efficacy and safety of OnabotulinumA in long-term, open-label study for the prophylaxis of headaches in adult chronic migraine patients: an interim analysis of the COMPEL study","volume":"84","author":"Blumenfeld","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2018.01.019_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.parkreldis.2012.02.007","article-title":"The Toronto western spasmodic Torticollis rating scale: reliability in neurologists and physiotherapists","volume":"18","author":"Boyce","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.toxicon.2018.01.019_bib12","first-page":"IO","article-title":"The action of botulinum toxin at the neuromuscular junction","volume":"I09","author":"Burgen","year":"1949","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.toxicon.2018.01.019_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1526-4610.2010.01796.x","article-title":"A\u00a0multi - center double - blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine","volume":"51","author":"Cady","year":"2011","journal-title":"Headache"},{"key":"10.1016\/j.toxicon.2018.01.019_bib14","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/0333102414561873","article-title":"Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year?","volume":"35","author":"Cernuda-Morollon","year":"2015","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2018.01.019_bib15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/eye.2009.192","article-title":"Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicenter study using two drug-dose escalation indexes","volume":"24","author":"Cillino","year":"2010","journal-title":"Eye"},{"key":"10.1016\/j.toxicon.2018.01.019_bib16","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of CD","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2018.01.019_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"U.S. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"35","key":"10.1016\/j.toxicon.2018.01.019_bib18","article-title":"Clinical practice: evidence-based recommendations for the treatment of cervical dystonia with botulinum toxin","volume":"8","author":"Contarino","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.toxicon.2018.01.019_bib19","doi-asserted-by":"crossref","DOI":"10.5334\/tohm.170","article-title":"Descriptive epidemiology of CD","author":"Defazio","year":"2013","journal-title":"TremorOther Hyperkinet"},{"key":"10.1016\/j.toxicon.2018.01.019_bib20","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"Onabotulinumt oxinA for treatment of chronic migraine: results from the double - blind, randomized, placebo - controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2018.01.019_bib21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/0269215511432016","article-title":"A\u00a0prospective, multicentre, randomized, double - blind, placebo - controlled trial of onabotulinumtoxinA to treat plantarflexor\/invertor overactivity after stroke","volume":"26","author":"Dunne","year":"2012","journal-title":"Clin. Rehabil."},{"key":"10.1016\/j.toxicon.2018.01.019_bib22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00702-007-0728-2","article-title":"From poison to remedy: the chequered history of botulinum toxin","volume":"115","author":"Erbguth","year":"2008","journal-title":"J.\u00a0Neural. Transm."},{"key":"10.1016\/j.toxicon.2018.01.019_bib23","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00702-013-1048-3","article-title":"A\u00a0randomized, double-blind study of repeated incobotulinumtoxinA(Xeomin) in CD","volume":"120","author":"Evidente","year":"2013","journal-title":"J.\u00a0Neural. Transm."},{"key":"10.1016\/j.toxicon.2018.01.019_bib24","article-title":"The history of botulinum toxin: from poison to beauty","author":"Franca","year":"2017","journal-title":"Wien Med. Wochenschr."},{"key":"10.1016\/j.toxicon.2018.01.019_bib25","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1474-4422(15)00216-1","article-title":"Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomizedcontrolled trial","volume":"14","author":"Gracies","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.toxicon.2018.01.019_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/10582450802161952","article-title":"Efficacy and safety of botulinum type A toxin in adductor spasticity due to multiple sclerosis","volume":"16","author":"Gusev","year":"2008","journal-title":"J.\u00a0Muscoskel. Pain"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.toxicon.2018.01.019_bib27","first-page":"11","article-title":"Some unresolved issues with botulinum toxin","volume":"248","author":"Guyer","year":"2001","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.toxicon.2018.01.019_bib28","first-page":"319","article-title":"Intramuscular injection of botulinum toxin for the treatment of wrist and fingerspasticity after stroke","volume":"62","author":"Jahangir","year":"2007","journal-title":"Med. J. Malaysia"},{"key":"10.1016\/j.toxicon.2018.01.019_bib29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm: a randomized trial","volume":"26","author":"Jankovic","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2018.01.019_bib30","first-page":"1330","article-title":"Botulinum toxin type A in post - stroke lower limb spasticity: a multicenter, double - blind, placebo - controlled trial","volume":"257","author":"Kaji","year":"2010","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.toxicon.2018.01.019_bib31","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1185\/03007995.2010.497103","article-title":"Botulinum toxin type A in post-stroke upper limb spasticity","volume":"26","author":"Kaji","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.toxicon.2018.01.019_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNF.0b013e3181b13308","article-title":"Efficacy and safety of botulinum neurotoxin NT 201 in post-stroke upper limb spasticity","volume":"32","author":"Kanovsk\u00fd","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.toxicon.2018.01.019_bib33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00702-014-1278-z","article-title":"Blepharospasm: long-term treatment with either Botox, Xeomin or Dysport","volume":"122","author":"Kollewe","year":"2015","journal-title":"J.\u00a0Neural. Transm."},{"key":"10.1016\/j.toxicon.2018.01.019_bib34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jamda.2012.03.005","article-title":"Can botulinum toxin decrease care burden in long term care residents with upper limb spasticity? A randomized controlled study","volume":"13","author":"Lam","year":"2012","journal-title":"J.\u00a0Am. Med. Dir. Assoc."},{"key":"10.1016\/j.toxicon.2018.01.019_bib35","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1212\/WNL.0b013e318232ab65","article-title":"OnabotulinumtoxinA improves quality of life and r educes impact of chronic migraine","volume":"77","author":"Lipton","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2018.01.019_bib36","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.3390\/toxins7093818","article-title":"Botulinum toxin type a as a therapeutic agent against headache and related disorders","volume":"7","author":"Luvisetto","year":"2015","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2018.01.019_bib37","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2340\/16501977-0672","article-title":"Effects of botulinum toxin A in ambulant adults with spastic cerebral palsy: a randomized double - blind placebo controlled - trial","volume":"43","author":"Maanum","year":"2011","journal-title":"J.\u00a0Rehabil. Med."},{"key":"10.1016\/j.toxicon.2018.01.019_bib38","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/PHM.0b013e31826ecb02","article-title":"Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity? A randomized, double-blind, placebo-controlled trial","volume":"91","author":"Marciniak","year":"2012","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"10.1016\/j.toxicon.2018.01.019_bib39","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2340\/16501977-0366","article-title":"Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centered outcomes","volume":"4","author":"McCrory","year":"2009","journal-title":"J.\u00a0Rehabil. Med."},{"key":"10.1016\/j.toxicon.2018.01.019_bib40","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1212\/01.wnl.0000311390.87642.d8","article-title":"Assessment: botulinum toxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"70","author":"Naumann","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2018.01.019_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/0019-5154.60343","article-title":"Botulinum toxin","volume":"55","author":"Nigam","year":"2010","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.toxicon.2018.01.019_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","article-title":"A\u00a0double-blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of CD","volume":"64","author":"Odergren","year":"1998","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2018.01.019_bib43","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","article-title":"Botulinum toxin type B vs. type Ain toxin-na\u00efve patients with CD: randomized,double-blind, noninferiority trial","volume":"23","author":"Pappert","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2018.01.019_bib44","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/1545968311430824","article-title":"Botulinum toxin injection for hyper-tonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial","volume":"26","author":"Rosales","year":"2012","journal-title":"Neurorehabil Neural Repair"},{"key":"10.1016\/j.toxicon.2018.01.019_bib45","doi-asserted-by":"crossref","DOI":"10.1097\/WNF.0000000000000101","article-title":"A\u00a0comparison of Botox 100 U\/mL and Dysport 100 U\/mL using dose conversion ratio 1: 3 and 1: 1.7in the treatment of CD: a double-blind, randomized,crossover trial","volume":"38","author":"Rystedt","year":"2015","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.toxicon.2018.01.019_bib46","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WNO.0000000000000110","article-title":"A\u00a0direct comparison of onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a splitface technique","volume":"34","author":"Saad","year":"2014","journal-title":"J.\u00a0Neuro Ophthalmol."},{"key":"10.1016\/j.toxicon.2018.01.019_bib47","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/STROKEAHA.110.582197","article-title":"Botulinum toxin for the upper limb after stroke (BoTULS) trial: effect on impairment, activity limitation,and pain","volume":"42","author":"Shaw","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.toxicon.2018.01.019_bib48","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/jnnp.2008.159657","article-title":"Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study","volume":"80","author":"Simpson","year":"2009","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2018.01.019_bib49","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2018.01.019_bib50","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, CD, adult spasticity, and headache: report of the guideline development subcommittee of the american Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurolog"},{"key":"10.1016\/j.toxicon.2018.01.019_bib51","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","article-title":"Long-term efficacy and safety of botulinum toxin type A (Dysport) in CD","volume":"16","author":"Truong","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.toxicon.2018.01.019_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.parkreldis.2007.11.003","article-title":"Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial","volume":"14","author":"Truong","year":"2008","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.toxicon.2018.01.019_bib53","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00702-013-0998-9","article-title":"Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin) injections in blepharospasm","volume":"120","author":"Truong","year":"2013","journal-title":"J.\u00a0Neural. Transm."},{"key":"10.1016\/j.toxicon.2018.01.019_bib54","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00702-010-0529-x","article-title":"Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm","volume":"118","author":"Wabbels","year":"2011","journal-title":"J.\u00a0Neural. Transm."},{"key":"10.1016\/j.toxicon.2018.01.019_bib55","first-page":"1073","volume":"248","author":"Wissel","year":"2001","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.toxicon.2018.01.019_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2340\/16501977-0303","article-title":"European consensys table on the use of Botulinum Toxin type A in adult spasticity","volume":"4","author":"Wissel","year":"2009","journal-title":"J.\u00a0Rehabil. Med."},{"key":"10.1016\/j.toxicon.2018.01.019_bib57","first-page":"347","article-title":"Increased levels of SV2A botulinum neurotoxin repcet in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons","volume":"4","author":"Yiangou","year":"2011","journal-title":"J.\u00a0Pain Res."},{"key":"10.1016\/j.toxicon.2018.01.019_bib58","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/mds.26085","article-title":"Dysport and Botox at a ratio of 2.5:1 units in CD: a double-blind,randomized study","volume":"30","author":"Yun","year":"2015","journal-title":"Mov. Disord."}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010118300333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010118300333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T23:25:31Z","timestamp":1719789931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010118300333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":58,"alternative-id":["S0041010118300333"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2018.01.019","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence on botulinum toxin in selected disorders","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2018.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}